Global Eye Health Company Signs Multi-Year Agreement to
Implement Phase Forward’s EDC Solution
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 29, 2009--
Phase Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, today announced a
multi-year contract with renowned eye health company Bausch & Lomb. The
agreement calls for Bausch & Lomb to implement Phase Forward’s InForm™
Global Trial Management (GTM) electronic data capture (EDC) solution,
including the Central Coding™ module, in all of its trials, including
Surgical, Vision Care and Pharmaceuticals products.
Bausch & Lomb will leverage Phase Forward’s InForm GTM to view and act
on clinical trial data earlier in the development cycle, and enhance the
efficiency and effectiveness with which it manages study procedures and
expenditures. The Central Coding module – fully integrated with InForm –
will be utilized to streamline the process of coding medical terms for
trials, automating manual tasks while increasing coding consistency and
accuracy.
“Bausch & Lomb is committed to the use of innovative technology to help
develop the highest quality eye health products in the most efficient
manner,” said John W. Sheets, Jr., corporate vice president and chief
technology officer, Bausch & Lomb. “Clinical trials are a critical
element of our product development engine, and Phase Forward’s EDC
solution brings a proven solution for automating and optimizing trial
management.”
“Bausch & Lomb enjoys a worldwide reputation for high quality eye health
products,” said Bob Weiler, chairman and CEO, Phase Forward. “We are
proud to be selected by a company of this caliber. Our mission is to
become the trusted partner of all of our customers, and we bring this
same commitment to this new relationship announced today.”
About Bausch & Lomb
Bausch & Lomb is dedicated to bringing visionary ideas to eye health.
Its core businesses include contact lenses and lens care products,
ophthalmic surgical devices and instruments, and ophthalmic
pharmaceuticals. The Bausch & Lomb name is one of the best-known and
most respected healthcare brands in the world. Founded in 1853, the
company is headquartered in Rochester, N.Y., and employs more than
10,000 people worldwide. Its products are available in more than 100
countries. More information is available at www.bausch.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. Phase Forward’s products
and services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 300
organizations and regulatory agencies worldwide including: AstraZeneca,
Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S.
Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International,
Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare
Products Regulatory Agency. Additional information about Phase Forward
is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based on
historical information are forward-looking statements which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things, the
performance and features of Phase Forward’s products and services,
demand for Phase Forward’s products and services, future business and
operations plans of a Phase Forward customer, and the ability of Phase
Forward’s customers to realize benefits from the use of Phase Forward’s
products and services. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond Phase Forward's control, which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties
include, among other things, the ability of Phase Forward’s customers to
realize benefits from the use of its products and services, the
possibility that customers’ needs or plans may change over time, the
possibility that the level of demand for Phase Forward’s products and
services may vary, regulatory changes and competition. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Phase Forward undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. For additional
disclosure regarding these and other risks faced by Phase Forward, see
the disclosure contained in Phase Forward's public filings with the
Securities and Exchange Commission including, without limitation, its
most recent Annual Report on Form 10-K.
Source: Phase Forward
Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN
PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com
